{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T11:40:37Z","timestamp":1781264437839,"version":"3.54.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1998,12,1]],"date-time":"1998-12-01T00:00:00Z","timestamp":912470400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biotherapy"],"published-print":{"date-parts":[[1998,12]]},"DOI":"10.1023\/a:1008099612354","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T12:45:23Z","timestamp":1040561123000},"page":"255-258","source":"Crossref","is-referenced-by-count":16,"title":["Levamisole and Interleukin-2 for advanced malignancy"],"prefix":"10.1007","volume":"11","author":[{"given":"Randall F.","family":"Holcombe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruby M.","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"182582_CR1","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3109\/07357909409023048","volume":"12","author":"RC Turowski","year":"1994","unstructured":"Turowski RC, Triozzi PL. Application of chemical im-munomodulators to the treatment of cancer and AIDS. Cancer Invest 1994; 12: 620.","journal-title":"Cancer Invest"},{"key":"182582_CR2","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1084\/jem.155.6.1823","volume":"155","author":"EA Grimm","year":"1982","unstructured":"Grimm EA, Mazumber A, Zhang HZ, Rosenbeg SA. Lymphocyte-activated killing phenomenon: lysis of natural killer resistant fresh solid tumor cells by interleukin-2 acti-vated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155: 1823.","journal-title":"J Exp Med"},{"key":"182582_CR3","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00000658-198910000-00008","volume":"210","author":"SA Rosenberg","year":"1989","unstructured":"3. Rosenberg SA, Lotze MT, Yang JC. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1989; 210: 474.","journal-title":"Ann Surg"},{"key":"182582_CR4","volume-title":"Therapeutic applications of interleukin-2","year":"1993","unstructured":"Atkins MB, Mier JW eds. Therapeutic applications of interleukin-2, New York, NY, Marcel Dekker, Inc., 1993."},{"key":"182582_CR5","doi-asserted-by":"crossref","unstructured":"van Haelst-Pisani CM, Pisani RJ, Kovach JS. Cancer im-munotherapy: current status of treatment with interleukin-2 and lymphokine-activated killer cells. Mayo Clin Proc 1989; 64: 451.","DOI":"10.1016\/S0025-6196(12)65736-X"},{"key":"182582_CR6","first-page":"349","volume":"272D","author":"G Renoux","year":"1971","unstructured":"Renoux G, Renoux M. Effet immunostimulant d'un imidoth-iazole dans l'immunisation des souris contre l'infection par Brucella abortus. CR Acad Sci 1971; 272D: 349.","journal-title":"CR Acad Sci"},{"key":"182582_CR7","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJM199002083220602","volume":"322","author":"CG Moertel","year":"1990","unstructured":"Moertel CG, Fleming TR, McDonald JS, Haller DG, Laurie JA, Goodman PJ, et al. Levamisole and fluorouracil for adju-vant therapy of resected colon carcinoma. New Engl J Med 1990; 322: 352.","journal-title":"New Engl J Med"},{"key":"182582_CR8","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1200\/JCO.1989.7.10.1447","volume":"7","author":"JA Laurie","year":"1989","unstructured":"Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, et al. Surgical adjuvant therapy of large-bowel car-cinoma: An evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 1989; 7: 1447.","journal-title":"J Clin Oncol"},{"key":"182582_CR9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/bjs.1800740707","volume":"74","author":"R Windle","year":"1987","unstructured":"Windle R, Bell PRF, Shaw D. Five year results of a ran-domized trial of adjuvant 5-fluorouracil and levamisole in colorectal cancer. Br J Surg 1987; 74: 569.","journal-title":"Br J Surg"},{"key":"182582_CR10","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2165\/00002512-199101040-00007","volume":"4","author":"P Chrisp","year":"1991","unstructured":"Chrisp P, McTavish D. Levamisole\/fluorouracil: A review of their pharmacology and adjuvant therapeutic use in colorectal cancer. Drugs & Aging 1991; 4: 317.","journal-title":"Drugs & Aging"},{"key":"182582_CR11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.1993.11.1.125","volume":"11","author":"J Janik","year":"1993","unstructured":"Janik J, Kopp WC, Smith JW, Longo DL, Alvord G, Sharfman WH, Fenton RG, Sznol M, Steis RG, Creekmore SP, Ewel CH, Hursey J, Urba WJ. Dose-related immunologic effects of levamisole in patients with cancer. J Clin Oncol 1993; 11: 125.","journal-title":"J Clin Oncol"},{"key":"182582_CR12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/BF01517209","volume":"34","author":"RF Holcombe","year":"1994","unstructured":"Holcombe RF, Stewart RM, Betzing KW, Kannan K. Alter-ation in lymphocyte phenotype associated with administration of adjuvant levamisole and 5-fluorouracil. Cancer Immunol Immunother 1994; 34: 394.","journal-title":"Cancer Immunol Immunother"},{"key":"182582_CR13","unstructured":"13. DeBrander M Vandebroek J, Wassenaar H, DeCree J, Braisier A, Demoen B, DeRidder R, Jagers E, Roels V, Vogels O. Immunological alterations induced by adjuvant treatment of postoperative colon carcinoma Duke's B or C with levamisole in combination with 5-FU. Anticancer Research 1995; 15: 2271."},{"key":"182582_CR14","first-page":"431","volume":"83","author":"RF Holcombe","year":"1994","unstructured":"Holcombe RF, Stewart RM, Kannan K. Levamisole is syner-gistic with IL12 in the stimulation of Th1 cells. Blood 1994; 83: 431a.","journal-title":"Blood"},{"key":"182582_CR15","first-page":"111","volume":"14","author":"JM Redondo","year":"1987","unstructured":"Redondo JM, Lopex-Guerrero JA, Fresno M. Potentiation of interleukin-2 activity by levamisole and imidazole. Immunol Lett 1987; 14: 111.","journal-title":"Immunol"},{"key":"182582_CR16","first-page":"288","volume":"9","author":"NI Obiri","year":"1990","unstructured":"Obiri NI, Dupere SL, Pruett SB, Lackey A, Emma D, O'Connor TE. Levamisole meets sulfhydryl requirements of CTLL-2 cells and mediates enhanced proliferative response to mitogen stimulation without increasing interleukin-2 produc-tion. J Biol Response Mod 1990; 9: 288.","journal-title":"J Biol Response Mod"},{"key":"182582_CR17","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/00000421-199408000-00013","volume":"17","author":"TG Call","year":"1994","unstructured":"Call TG, Creagan ET, Frytak S, Buckner JC, van Haelst-Pisani C, Homburger HA, Katzmann JA. Phase I trial of combined recombinant interleukin-2 with levamisole in patients with advanced malignant disease. Am J Clin Oncol 1994; 17: 344.","journal-title":"Am J Clin Oncol"},{"key":"182582_CR18","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/bjc.1996.498","volume":"74","author":"FY Ahmed","year":"1996","unstructured":"Ahmed FY, Leonard GA, A'Hern R, Taylor AE, Lorentzos A, Atkinson H, Moore J, Nicolson MC, Riches PG, Gore ME. A randomised dose escalation study of subcutaneous interleukin 2 with and without levamisole in patients with metastatic renal cell carcinoma or malignant melanoma. Br J Cancer 1996; 74: 1109.","journal-title":"Br J Cancer"},{"key":"182582_CR19","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1084\/jem.161.6.1575","volume":"161","author":"TR Malek","year":"1985","unstructured":"Malek TR, Ashwell JD. Interleukin 2 upregulates expression of its receptor on a T cell clone. J Exp Med 1985; 161: 1575.","journal-title":"J Exp Med"},{"key":"182582_CR20","doi-asserted-by":"crossref","unstructured":"Rubin LA, Nelson DL. The soluble interleukin-2 receptor: Biology, function, and clinical application. Ann Int Med 1990; 113: 619.","DOI":"10.7326\/0003-4819-113-8-619"}],"container-title":["Biotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1008099612354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1008099612354\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1008099612354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T17:37:58Z","timestamp":1749577078000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1008099612354"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1998,12]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1998,12]]}},"alternative-id":["182582"],"URL":"https:\/\/doi.org\/10.1023\/a:1008099612354","relation":{},"ISSN":["0921-299X","1573-8280"],"issn-type":[{"value":"0921-299X","type":"print"},{"value":"1573-8280","type":"electronic"}],"subject":[],"published":{"date-parts":[[1998,12]]}}}